Lynn Morris
#164,876
Most Influential Person Now
Researcher
Lynn Morris's AcademicInfluence.com Rankings
Lynn Morriscomputer-science Degrees
Computer Science
#9806
World Rank
#10288
Historical Rank
Artificial Intelligence
#4741
World Rank
#4804
Historical Rank
Database
#6760
World Rank
#6998
Historical Rank
Download Badge
Computer Science
Lynn Morris's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Lynn Morris Influential?
(Suggest an Edit or Addition)Lynn Morris's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women (2010) (2178)
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma (2021) (724)
- Structure and immune recognition of trimeric prefusion HIV-1 Env (2014) (682)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (2014) (675)
- Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia (2008) (610)
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma (2021) (520)
- Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? (2009) (476)
- The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection (2011) (456)
- Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors (2011) (420)
- Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa (2006) (379)
- Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C (2008) (369)
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women: Supporting Online Material (2010) (359)
- Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 (2006) (349)
- Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration (2005) (337)
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection (2007) (336)
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape (2012) (296)
- Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines (2005) (255)
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa (2020) (255)
- Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. (2005) (254)
- Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection (2009) (240)
- Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 (2001) (230)
- Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study (2008) (214)
- Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization (2013) (210)
- The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C (2003) (209)
- Antigen markers of macrophage differentiation in murine tissues. (1992) (204)
- Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes (2013) (196)
- The Antibody Response against HIV-1. (2012) (196)
- Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. (1991) (196)
- Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals (2011) (190)
- Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies (2015) (190)
- New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency (2015) (187)
- Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors (2009) (186)
- The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection (2007) (182)
- Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies (2017) (176)
- Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (173)
- Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop (2011) (173)
- Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein (2012) (172)
- Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016) (155)
- Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting (2011) (155)
- Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. (2006) (154)
- A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences (2006) (154)
- Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (2015) (152)
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. (2021) (148)
- Heterogeneity in Lymphokine Profiles of CD4+ and CD8+ T Cells and Clones Activated in vivo and in vitro (1991) (145)
- High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity (2019) (141)
- Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection (2016) (136)
- Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. (2003) (134)
- Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. (2004) (132)
- Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. (2009) (131)
- The Development of CD4 Binding Site Antibodies during HIV-1 Infection (2012) (129)
- Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa (2002) (127)
- International Network for Comparison of HIV Neutralization Assays: The NeutNet Report (2009) (124)
- Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa (2010) (121)
- HIV broadly neutralizing antibody targets (2015) (120)
- Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design (2013) (119)
- Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. (2014) (115)
- Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission (2006) (114)
- International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II (2009) (113)
- Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region (2009) (110)
- Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent (2006) (108)
- High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. (2009) (107)
- Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa (2011) (105)
- Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004 (2008) (105)
- Potent and broad HIV-neutralizing antibodies in memory B cells and plasma (2017) (101)
- Changes in the precursor frequencies of IL-4 and IFN-gamma secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis. (1992) (100)
- HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. (2014) (96)
- HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes (2006) (95)
- Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. (2009) (93)
- Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine (2007) (92)
- Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B (2006) (91)
- Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants (2008) (91)
- Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. (2009) (90)
- Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge (2017) (90)
- Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. (2010) (89)
- Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. (2003) (88)
- Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. (2010) (88)
- Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) (2021) (88)
- CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. (2001) (86)
- Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis (2014) (82)
- Does tuberculosis increase HIV load? (2004) (81)
- Interleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis (1993) (81)
- Virological features associated with the development of broadly neutralizing antibodies to HIV-1. (2015) (80)
- Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization (2016) (78)
- Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study (2011) (78)
- Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection (2016) (76)
- Specificity of the autologous neutralizing antibody response (2009) (75)
- Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection (2018) (75)
- Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial (2018) (74)
- Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies (2013) (74)
- Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. (2006) (74)
- Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point (2008) (72)
- Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide (2017) (72)
- Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma (2008) (72)
- Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection (2014) (72)
- Neutralization tiers of HIV-1 (2017) (70)
- Characterization of full-length HIV type 1 subtype C sequences from South Africa. (2001) (70)
- Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. (2018) (69)
- Novel cell surface adhesion receptors involved in interactions between stromal macrophages and haematopoietic cells (1988) (69)
- HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. (2008) (67)
- Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire (2015) (66)
- Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. (2015) (65)
- Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual (2011) (62)
- Characterization of human blood dendritic cells: cytokine profiles. (1995) (60)
- Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. (2013) (59)
- World Health Organization/HIVResNet Drug Resistance Laboratory Strategy (2008) (58)
- Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting (2017) (58)
- HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine (2011) (57)
- Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (57)
- Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. (2014) (57)
- Localization and function of tissue macrophages. (1986) (57)
- Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. (2002) (57)
- Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site (2011) (56)
- N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization (2007) (56)
- Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. (2006) (56)
- Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch (2013) (55)
- HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies (2018) (55)
- Genetic characterization of HIV type 1 from migrant workers in three South African gold mines. (1998) (55)
- Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape (2017) (54)
- Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. (2015) (54)
- Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. (2012) (54)
- Use of alternate coreceptors on primary cells by two HIV-1 isolates. (2005) (53)
- Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. (2007) (53)
- Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. (2005) (52)
- The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. (2012) (51)
- IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody (2019) (50)
- Murine fetal liver macrophages bind developing erythroblasts by a divalent cation-dependent hemagglutinin (1988) (49)
- Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. (2016) (49)
- Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype C (2011) (48)
- Meningitis in a community with a high prevalence of tuberculosis and HIV infection (1999) (46)
- Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. (2012) (46)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions (2021) (46)
- Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors (2014) (45)
- Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. (2006) (43)
- Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. (2007) (43)
- HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. (2002) (43)
- Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire (2007) (43)
- Rapid disease progression in HIV-1 subtype C-infected South African women. (2014) (42)
- Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis (2019) (42)
- HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South Africa. (2002) (41)
- Virus Entry via the Alternative Coreceptors CCR3 and FPRL1 Differs by Human Immunodeficiency Virus Type 1 Subtype (2009) (41)
- Expression of a divalent cation-dependent erythroblast adhesion receptor by stromal macrophages from murine bone marrow. (1991) (41)
- UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C (2012) (41)
- 4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response (2007) (41)
- Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study (2008) (40)
- Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. (2004) (40)
- Emergence of Individuality in Genetically Identical Mice (2013) (40)
- Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine (2003) (40)
- Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. (2011) (40)
- Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa (2019) (38)
- Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope (2017) (38)
- Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. (2005) (38)
- Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. (2020) (37)
- A model of directional selection applied to the evolution of drug resistance in HIV-1. (2007) (36)
- HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes (2018) (36)
- Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. (2011) (36)
- Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity (2016) (35)
- The complex challenges of HIV vaccine development require renewed and expanded global commitment (2019) (34)
- Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. (2007) (33)
- Phylogenetic analysis of human herpesvirus-8 in South Africa and identification of a novel subgroup. (2000) (33)
- A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1* (2014) (33)
- AIDS-related mycoses: the way forward. (2014) (33)
- Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. (2005) (32)
- Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. (2012) (31)
- SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies (2021) (31)
- Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. (2011) (31)
- Identification of HIV type 1 intersubtype recombinants in South Africa using env and gag heteroduplex mobility assays. (2000) (29)
- Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection (2016) (29)
- Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. (2001) (28)
- Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies (2017) (27)
- Prospects for passive immunity to prevent HIV infection (2017) (27)
- Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site (2016) (27)
- Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens (2019) (27)
- Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies (2017) (27)
- Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. (2007) (26)
- Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. (1994) (26)
- Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination (2007) (26)
- Measuring the ability of HIV-specific antibodies to mediate trogocytosis. (2018) (26)
- Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus (2019) (26)
- AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region (2019) (25)
- Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap (2016) (25)
- Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. (2013) (24)
- V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity (2018) (24)
- Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. (2009) (24)
- Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage (2015) (23)
- Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments (2017) (23)
- South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication (2015) (22)
- Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa (2013) (22)
- Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines (2020) (22)
- HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth (2018) (22)
- Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 (2018) (21)
- Full-length genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. (2003) (21)
- A new, sensitive polynucleotide probe for distinguishing Candida albicans strains and its use with a computer assisted archiving and pattern comparison system. (1992) (21)
- Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa (2017) (21)
- HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms (2016) (20)
- Resistance of BALB/c mice to Leishmania major infection is associated with a decrease in the precursor frequency of antigen-specific CD4+ cells secreting interleukin-4. (1993) (20)
- Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications (2020) (19)
- HIV-1 Subtype C Unproductively Infects Human Cardiomyocytes In Vitro and Induces Apoptosis Mitigated by an Anti-Gp120 Aptamer (2014) (19)
- Neutralizing Antibody Responses to HIV‐1 Infection (2002) (19)
- Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G (2004) (18)
- Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway (2019) (18)
- Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia (2015) (18)
- Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals (2009) (18)
- High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults (2018) (18)
- Antibodies against human herpesvirus 8 in South African renal transplant recipients and blood donors (2004) (18)
- Expression of functional recombinant human procathepsin B in mammalian cells. (1996) (18)
- Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. (2009) (18)
- Ricin-resistant mutants of Leishmania major which express modified lipophosphoglycan remain infective for mice (1994) (18)
- Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. (2010) (17)
- Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant (2021) (17)
- Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (17)
- Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants (2016) (17)
- Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial (2020) (17)
- Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy (2016) (17)
- The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256 (2018) (17)
- Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel (2015) (16)
- Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions (2018) (16)
- Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. (2014) (16)
- In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. (2005) (16)
- Phenotypic characterization of HIV type 1 isolates from Ghana. (2007) (16)
- Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women (2016) (16)
- Identification of cell subsets expressing intracytoplasmic cytokines within HIV‐1‐infected Iymph nodes (1996) (16)
- Novel indole based NNRTIs with improved potency against wild type and resistant HIV. (2014) (15)
- Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. (2005) (14)
- Durable HIV RNA resuppression after virologic failure while remaining on a first‐line regimen: a cohort study (2014) (14)
- Developmental Regulation of Sialoadhesin (Sheep Erythrocyte Receptor), a Macrophage-Cell Interaction Molecule Expressed in Lymphohemopoietic Tissues (1992) (14)
- Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein (2020) (14)
- Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa (2011) (13)
- Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope (2019) (13)
- Usefulness of HIV-1 V3 serotyping in studying the HIV-1 epidemic in South Africa. (1998) (13)
- Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. (2015) (13)
- Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. (2006) (13)
- Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa (2003) (12)
- Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes (2016) (12)
- Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage (2018) (12)
- Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape (2020) (11)
- Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies (2018) (11)
- Mannose-rich glycosylation patterns on HIV-1 subtype C gp 120 and sensitivity to the lectins (2011) (11)
- The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection. (2020) (11)
- HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial (2015) (11)
- Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions (2003) (11)
- Common helical V1V2 conformations of HIV-1 Envelope expose the alpha 4 beta 7 binding site on intact virions. (2018) (11)
- Molecular investigation of two possible cases of accidental HIV-1 transmission in South Africa. (2003) (10)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (10)
- Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract (2019) (10)
- Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to alpha4beta7 (2018) (10)
- Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection (2011) (10)
- Development of Phenotypic HIV-1 Drug Resistance After Exposure to Single-Dose Nevirapine (2008) (10)
- Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13 (2019) (10)
- Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up (2012) (10)
- The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. (2015) (9)
- Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. (2015) (9)
- HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function (2021) (9)
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial (2019) (9)
- Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses (2017) (9)
- Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. (2014) (8)
- Adhesion receptors involved in the erythroblastic island. (1991) (8)
- Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition (2022) (8)
- Coreceptor Usage and Biological Phenotypes of HIV-1 Isolates (2002) (8)
- Progress towards developing a vaccine to prevent HIV and AIDs in South Africa. (2001) (7)
- Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions (2020) (7)
- Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (7)
- HIV-1 drug resistance and mother-to-child transmission. (2001) (7)
- High specificity of V3 serotyping among human immunodeficiency virus type‐1 subtype C infected patients with varying disease status and viral phenotype (2006) (7)
- HIV/AIDS in South Africa: Viral structure, replication, tropism, pathogenesis and natural history (2010) (7)
- Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. (2017) (6)
- Host and viral factors that impact on HIV-1 transmission and disease progression in South Africa. (2001) (6)
- Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. (2014) (6)
- Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children (2019) (6)
- Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent (2004) (6)
- Cellular interactions between stromal macrophages and haematopoietic cells (1992) (5)
- Integrin VLA-2 (a2ßi)Function in Postextravasation Movement of Human Rhabdomyosarcoma RD Cells in the Liver1 (2006) (5)
- Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage (2019) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants (2021) (4)
- ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection (2021) (4)
- UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance (2016) (4)
- P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group (2009) (4)
- Provincial and National Prevalence Estimates of Transmitted HIV-1 drug Resistance in South Africa Measured using two WHO-recommended Methods (2019) (4)
- HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies. (2018) (4)
- Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. (2020) (3)
- Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth (2021) (3)
- Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection (2020) (3)
- High-Throughput B Cell Epitope Determination by Next-Generation Sequencing (2022) (3)
- Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. (2019) (3)
- Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. (2012) (3)
- HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance (2020) (3)
- The importance of doing HIV research in developing countries (1998) (3)
- Broadly Neutralizing Antibodies (2017) (3)
- Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials (2020) (3)
- Correction for Hraber et al., “Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments” (2018) (3)
- Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies (2021) (3)
- Prevention of mother-to-child transmission : a report-back from the XV International AIDS Conference, Bangkok, 11-16 July 2004 (2004) (3)
- Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes (2003) (3)
- Where are we going with HIV vaccines (2009) (3)
- Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences. (2019) (3)
- No evidence for naturally occurring mutations resistant to HIV-1 reverse-transcriptase inhibitors among South African HIV-1 subtype C isolates (2000) (3)
- The stability of phylogenetic tree construction of the HIV-1 virus using genome-ordering data versus env gene data (2003) (2)
- Should South Africa be preparing for HIV-1 vaccine efficacy trials? (1997) (2)
- Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G (2005) (2)
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines (2021) (2)
- Interactions between nevirapine resistance mutations and NRTI resistance mutations (2005) (2)
- Promoting HIV vaccine research and development in southern Africa. (1997) (2)
- Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms (2022) (2)
- Selection of resistance following first-line anti-retroviral regimens among HIV-1 subtypes (2005) (2)
- Structure of Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition (2019) (2)
- Early virological suppression despite high frequency NNRTI resistance following perinatal prophylaxis in HIV-infected African infants (2008) (2)
- AIDS dissidents aren't victims — but the people their ideas kill will be (2000) (2)
- Entry inhibition of HIV-1 subtype C isolates (2007) (2)
- Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission (2021) (2)
- Up-Regulation of Transforming Growth Factor a Expression by Transforming Growth Factor fl , Epidermal Growth Factor , and N , N-Dimethylformamide in Human Colon Carcinoma Cells 1 (2005) (2)
- Afri-Can Forum 2 (2016) (2)
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention (2022) (2)
- Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models (2013) (1)
- Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses (2022) (1)
- Correction for Anthony et al., “Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope” (2018) (1)
- Drug Susceptibility and Replication Capacity of a Rare HIV-1 Subtype C Protease Hinge Region Variant (2019) (1)
- Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages (2021) (1)
- S12.3 Understanding How Broadly Cross-Neutralising Antibodies Develop in HIV Infection - Clues For HIV Vaccine Development? (2013) (1)
- Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms (2021) (1)
- Effect of subcellular targeting on the expression and accumulation of Griffithsin in N. benthamiana (2010) (1)
- Influence of subtype and treatment on genetic profiles of HIV-1 reverse transcriptase and protease: do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences? (2002) (1)
- The macrophage-blood interface: Cell localisation and recruitment in bone marrow, liver and brain (1987) (1)
- Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. (2023) (1)
- Germline Ig Gene Repertoire HIV-1 Antibodies Is Not Restricted by the Ability To Develop Broadly Neutralizing (2015) (1)
- P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape (2009) (1)
- Erratum: Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel (Mucosal Immunology (2016) 9, (834)) doi:10.1038/mi.2016.21 (2016) (1)
- Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group (2008) (1)
- Sequence and functional characterization of a public HIV-specific antibody clonotype (2021) (1)
- Engineered HIV antibody passes muster. (2019) (1)
- Comparison of the neutralization sensitivity of South African and Indian HIV-1 subtype C viruses to South African plasma antibodies (2012) (1)
- Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization (2017) (1)
- 116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection (2012) (1)
- HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights (2017) (1)
- Neutralization tiers of HIV-1 The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2018) (0)
- HIV-1 pseudovirus neutralisation by a natural compound: a potential microbicide (2011) (0)
- Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions (2018) (0)
- Virus Entry via the Alternative Coreceptors CCR3 and FPRL1 Differs by Human Immunodeficiency Virus Type 1 Subtype (cid:1) † (2009) (0)
- A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage (2019) (0)
- A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies (2017) (0)
- Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression (2012) (0)
- HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms (2016) (0)
- From Bench to Bedside: Lessons from HIV Natural History Cohort Studies (2017) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates (2012) (0)
- Binding of CAP206-CH12 mAb and CAP206-CH12 RUA to gp41 MPER peptide and gp41-inter protein. (2011) (0)
- HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies (2022) (0)
- P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors (2009) (0)
- N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization (cid:1) (2007) (0)
- Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies (2022) (0)
- Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition (2022) (0)
- HIV Vaccine and Passive Immunity Trials (2017) (0)
- Frequent generation of HIV broadly neutralizing antibodies in infected children is associated with both increased help and regulation within germinal centers (2018) (0)
- HIV-1 V 1 V 2 antibody with exceptional potency 5 6 (2015) (0)
- Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies (2014) (0)
- Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a heterologous CAP225 V1V2 (2018) (0)
- Development of aptamer based HIV-1 entry inhibitor prophylactic drugs (2013) (0)
- Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity (2012) (0)
- Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12 (2012) (0)
- Accumulating resistance of CAP257 clones to broadly neutralizing monoclonal antibodies targeting V2 and the CD4bs. (2013) (0)
- P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization (2009) (0)
- Strategy for Immunogen Design CCR 5 Utilization and Suggests a New Identifies Differences in Glycosylation and C Human Immunodeficiency Virus Type 1 Acute and Chronic Infections with Subtype Comparison of Viral Env Proteins from (2013) (0)
- Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications (2020) (0)
- Crystal structure of a V2-directed, RV144 vaccine-like antibody from HIV-1 infection, CAP228-16H, bound to a heterologous V2 peptide (2018) (0)
- Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition – A Nested Case-Control Study in HIV-1 Serodiscordant Couples (2022) (0)
- HIV vaccines: a new era? (1999) (0)
- Subtype C-Infected Individual HIV-1 Neutralizing-Antibody Response in an Represents the Initial Autologous Targets the Alpha-2 Helix of gp120 and Isolation of a Monoclonal Antibody That (2011) (0)
- Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel (2016) (0)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation (2018) (0)
- Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor (2023) (0)
- Resistance in the context of Mother-to-Child transmission Mother-to-child transmission of minority HIV-1 drug resistant strains (2005) (0)
- Crystal structure of human Fab CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody (2014) (0)
- Studies on multiply exposed but persistently HIV-1 seronegative sex workers from KwaZulu/Natal, South Africa (2000) (0)
- South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication (2015) (0)
- Neutralization of several adult and paediatric HIV-1 subtype C isolates using a shortened synthetic derivative of gp120 binding aptamer called UCLA1. (2009) (0)
- Structural Constraints of V accine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting (2015) (0)
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines (2022) (0)
- Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage (2022) (0)
- Effects of in vivo priming on the expression of IL-4 and IFN-γ in short-term murine T cell clones (1991) (0)
- Procede de selection d'isolats de sous-type c du vih-1, isolats de sous-type c du vih-1 selectionnes, genes, modifications et derives (2001) (0)
- Crystal structure of unliganded CH59UA, the inferred unmutated ancestor of the RV144 anti-HIV antibody lineage producing CH59 (2015) (0)
- Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject (2012) (0)
- CONFERENCE REPORT Prevention of mother-to-chi ld Transmission (2004) (0)
- Effect of expressing an anti-HIV lectin, Griffithsin, in different plant cellular compartments (2010) (0)
- Advancing HIV Vaccine Research With Low-Cost High-Performance Computing Infrastructure: An Alternative Approach for Resource-Limited Settings (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lynn Morris?
Lynn Morris is affiliated with the following schools:
